Results 21 to 30 of about 4,006,149 (207)

Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS

Frontiers in Oncology, 2023
Purpose The aim of the present study was to establish a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for the determination of SHR9146, a novel IDO1/TDO dual inhibitor, in mouse plasma and tissues, and to apply it to investigate the ...
Taijun Hang
exaly   +2 more sources

Tryptophan metabolism in colorectal cancer: From mechanistic insights to novel therapeutic strategies. [PDF]

Clin Transl Med
Tryptophan metabolism modulates CRC via three microbiota‐regulated pathways with distinct dual‐mode effects. The kynurenine pathway provides biomarkers, serotonin pathway supports SSRI‐combined immunotherapy, indole pathway yields immunostimulatory metabolites, collectively offering translational prospects.
Wang R, Shen W, Yang P, Yang D, Cao Y, Zhou Y.   +5 more
europepmc   +2 more sources

Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205. [PDF]

Clin Cancer Res
Purpose: We conducted a phase I trial to evaluate radiotherapy (RT) and nivolumab with the further addition of an indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitor (BMS-986205) in newly diagnosed patients with glioblastoma (GBM) IDH wild-type ...
Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M, Bommi P, Dixit K, Kumthekar P, Sharp L, Lezon R, Garcia D, Sonabend AM, McCortney K, Castro BA, Chandler JP, Gondi V, Grimm SA, Miska JM, Heimberger AB, Dobinda K, Zhang H, Sachdev S, Juhasz C, James CD, Allen JM, Horbinski C, Lesniak MS, Stupp R, Wainwright DA.   +29 more
europepmc   +2 more sources

Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells [PDF]

Frontiers in Immunology
The tryptophan-degrading enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a plastic immune checkpoint molecule that potently orchestrates immune responses within the tumor microenvironment (TME).
Sofia Rossini, Sara Ambrosino, Claudia Volpi, Maria Laura Belladonna, Maria Teresa Pallotta, Eleonora Panfili, Chiara Suvieri, Antonio Macchiarulo, Giada Mondanelli, Ciriana Orabona   +9 more
doaj   +2 more sources

Cancer IDO1‐Mediated Tryptophan–Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3‐dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is
Leng Han, Lingjie Jing, Xinting Zhu, Ciqin Li, Lu Bai, Yang Fang, Yuxuan Zhou, Dingyuan Bai, Jin Lu, Yonglong Han, Cheng Guo, Shumin Zhou, Quanjun Yang   +12 more
doaj   +2 more sources

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies [PDF]

International Journal of Nanomedicine
Kehua Jiang,1 Qing Wang,1 Xiao-Long Chen,1 Xiaodong Wang,1 Xiaoya Gu,1 Shuangshuang Feng,1 Jian Wu,2 Haojie Shang,2 Xiaozhuo Ba,2 Yanlong Zhang,1 Kun Tang2 1Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic ...
Jiang K, Wang Q, Chen XL, Wang X, Gu X, Feng S, Wu J, Shang H, Ba X, Zhang Y, Tang K   +10 more
doaj   +1 more source

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Gynecologic Oncology, 2017
Vadim Shirinkin, Igor Bondarenko, Vera Gorbunova   +2 more
exaly   +2 more sources

Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1.

Journal of Medicinal Chemistry, 2016
Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy. A number of IDO1 inhibitors have been identified, but only limited structural biology studies of IDO1 inhibitors are available ...
Yi-Hui Peng, S. Ueng, Chen-Tso Tseng, Ming-Shiu Hung, Jen-Shin Song, Jian-Sung Wu, Fang-Yu Liao, Yu-Shiou Fan, Mine-Hsine Wu, Wen-Chi Hsiao, Ching-Cheng Hsueh, Shu-Yu Lin, Chia-Yi Cheng, Chih-Hsiang Tu, Lung-Chun Lee, Ming-Fu Cheng, Kak‐Shan Shia, C. Shih, Su-Ying Wu   +18 more
semanticscholar   +4 more sources

Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma

Frontiers in Immunology, 2021
In chimeric antigen receptor (CAR)-T cell therapy, the role and mechanism of indoleamine 2, 3 dioxygenase 1 (IDO1) in enhancing antitumor immunity require further study.
Jingwen Shao, Jingwen Shao, Lin Hou, Lin Hou, Jinyan Liu, Yulin Liu, Jie Ning, Qitai Zhao, Yi Zhang, Yi Zhang, Yi Zhang, Yi Zhang   +11 more
doaj   +1 more source

IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10

Pharmacological Research, 2022
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in tryptophan catabolism along the kynurenine (Kyn) pathway and exerts immunosuppressive properties mainly via activation of transcription factor aryl hydrocarbon receptor (AhR ...
Xin Fang, Leilei Guo, Zikang Xing, Lei Shi, Heng Liang, Aiying Li, Chunxiang Kuang, Bangbao Tao, Qing Yang   +8 more
doaj   +1 more source